Daily Racing Form expert handicapper and analyst Scott Ehlers handicaps the Thursday, October 29 racing card at Churchill Downs, including his projected 1-2-3 finishers. His best bet of the day comes from Race 9.

Also, view FREE DRF Past Performances for today’s Race of the Day.

BEST BET: Social Belle (9th Race)

Ninth Race

1. Social Belle

2. Mobula

3. Grade A

SOCIAL BELLE had improved her Beyer speed figure in every race until her return start at Keeneland. Breaking 10th of 12 cost her everything, even if she still passed a few home. Win rider returns in Rodriguez. We like that connections keep the faith for a second grass start. Race flow is more than fair. MOBULA goes from one top barn to another. This hard-trying filly is bred to love a turf sprint with Tommies of 360/402. This filly draws outside main pace foes. GRADE A might be a horse for course before anyone knows it. She ran 3rd, beaten only by a neck in her local sod debut and did so at 18-1. She was denied a clean start in her second try and then didn’t care for two turns in her third. She can fire fresh and has some solid works.

Here are Scott’s thoughts on the other nine races on Thursday’s Churchill Downs card.

First Race

1. Mr. Tallymon

2. Quentin B

3. Bright Skittle

MR. TALLYMON is by a 21% debut sire (nice). His dam was un-raced. One of two sibs won and is 7-1-2-1 while banking 57K. Works are well spaced all for a barn that is 21% with their debut maidens. A weight break rounds out the appeal. QUENTIN B showed promise at Gulfstream and was thought enough of to ship here. Sure he faltered in his local debut but notice that he got some play when sent off at 3-1. Second time on this surface could make all the difference. BRIGHT SKITTLE has speed and draws outside for possibly the best trip. Main pace foe is stuck on the rail. A beaten favorite in three of five starts is the main knock. BEMIS exits a key race where 2 of 7 returned to win with figs of 78 and 56 (another finished 2nd with a 55 Beyer).

Second Race

1. Spencerian

2. Taqdeer

3. Musical Prayer

SPENCERIAN does get some pace to chase. New barn is 14% off the claim. This mare cuts back a full furlong, and we are betting that six panels is her best distance. Would a 77 Beyer win this? The par is 73 for this level. This 6YO won easy five back and did so going this distance at Laurel all while passing foes. That is the trip we want. TAQDEER is the outside speed. She just got a nice confidence boost over at Penn National. She has yet to run poorly on this dirt. Team Jacobson is 18% with their repeating winners. Oh, she exits a key race where 2 of 2 returned to win with figs of 63 and 55. MUSICAL PRAYER was a step slow in her most recent all while reunited with team Asmussen. Can this mare stalk? Any chance she is quickest? A good break is first and foremost. Recent works are well spaced.

Third Race

1. Reza

2. Ruiva

3. Cactus Closer

REZA is by a 0 for 2 debut turf sire. His dam never tried the grass nor did lone sibling. Horses that like the synth down at Gulfstream often like the grass anywhere. This gelding sure looked good in his debut and we like that connections shipped here to run for more money. Team Moubarak are 21% with their first turfers and they show a big flat bet profit. RUIVA has never run poorly. Hers are the best figs and foes. Other speed is a worry but good horses often find a way. Cross entered for BC day so who knows if she opts for this. CACTUS CLOSER pushed the pace in his first two starts and then passed runners in his most recent. Who doesn’t like versatile runners? He draws ideally and cuts back a half furlong. That distance Tomlinson of 404 screams short sprint. NESSY is by an 18% debut turf sire. His dam was un-raced and this is her first grass foal.

Fourth Race

1. Getting After It

2. Mustang Lady

3. Watershed Moment

GETTING AFTER IT returns to two turns and perhaps for the best. Her previous two routes came before the long layoff, and we have excuses for both. The first was versus stakes foes at Turfway, and she was only 3 1/2 lengths back with a furlong to go before she spit the bit. She caught a sloppy Joe surface in her second route at Keeneland. Her last two starts were a tad better so now is a good time to stretch-out. MUSTANG LADY loves to settle for less. Team Asmussen re-claimed this horse last out and for more than what they lost her for. When last seen going two turns, this mare finished second at 5-1 and did so here. WATERSHED MOMENT took twelve starts to break her maiden. What if she got a taste of winning and liked it? These types often return to outrun their odds. An early breather would go a long way.

Fifth Race

1. Big Luz

2. Boss Lady Kar

3. Texas Dandelion

BIG LUZ is an Indiana-bred that opts for this class drop rather than ship to Horseshoe Indy and face state-breds. Doesn’t that say everything? Team McPeek are 18% with their second-time maidens and 16% going special weight to maiden claimer. Two of four sibs beat winners and earned 251K and 105K. BOSS LADY KAR ran well in both starts to date even though they were two turns on the sod at Horseshoe Indy. That last race came back key when 2 of 4 returned to win with figs of 45 and 56. We bet a one turn mile is a good fit. TEXAS DANDELION did run quite well in her first two starts and both came here. Toga foes are tough three back. Was 7 1/2 furlongs too far off the bench? Class drop for hot barn could be all she wrote. HIGHER CALLING is by a 0 for 51 debut sire. Her dam went 17-1-4-2 and earned 29K. Both sibs raced and are winless. DREAM ABOUT exits a key common race where 2 of 5 returned to win with figs of 37 and 59 (another finished 2nd with a 56 Beyer).

Sixth Race

1. Paseo

2. Charm of Venice

3. Struck at Midnight

PASEO just ran a Beyer top and did so going longer on the grass. Connections find a similar spot today. Race flow isn’t fast but it isn’t pace-less either. This filly ran great the last time she tried this sod and that was 9 furlongs off a layoff. CHARM OF VENICE ran better when second time in the U.S. and now strings three races together for the first time. Gaffalione is a good fit for this horse, while two recent works are just right. STRUCK AT MIDNIGHT has some tactical speed at least in this race. She gets to save all the early ground all with Mr. Ortiz up (24% for team Sharp). Yet to run this far is a small X factor. We spy at least three works since her last race and you have to like that.

Seventh Race

1. Guardian

2. White Whale

3. Stay for the Boom

GUARDIAN might prove quickest in here, and if so, then an early breather is in play. He has gotten the lead at the first call in his last five starts. That was a solid effort last out, and it was his first for team Foster. This gelding cuts back two furlongs but we still think he is quickest. WHITE WHALE is 2 for 8 here and 0 for 11 anywhere else. He got a nice confidence boost last out all for a barn that is 24% with their repeating winners. STAY FOR THE BOOM did beat over half the field home previously and that was his first start locally. Some of those SoCal sprints fit. Check out those fast recent works. An early tote check could prove fortuitous.

Eighth Race

1. Positano John

2. We Be Mischief

3. Alworth

POSITANO JOHN is by a 11% debut sire. His dam was un-raced. Two of three siblings won and both beat winners (66K and 63K). Works are very nice, including that October 9th drill where this colt was 2nd best of 27. Was that bullet work on October 16th even better? Does team Bauer have this guy right where they want him, hence that recent work which wasn’t as quick? Seven panels is tough in a debut but at least this guy draws best with the attack post on his resume. WE BE MISCHIEF broke sharp in his debut and then ran great. This gelding didn’t cost 575K for nothing. ALWORTH has speed, and there isn’t much proven zip in here. He draws more outside today and did just miss going this distance previously. COWBOYS TIME is by a 16% debut sire. His dam was un-raced. One of three sibs won but only once. NAVIGATE exits a key race where 2 of 6 returned to win with figs of 77 and 73 (another pair finished 2nd with Beyer speed figures of 74 and 71).

Tenth Race

1. Wavefront

2. Elvis Tony

3. Mayweather

WAVEFRONT is by a 11% debut sire. His dam went 21-2-3-5 and earned 83K. Lone sibling is 12-4-1-2 and earned 103K. We love that Jose takes the call (30% for this barn). Louisiana Downs works will help the price. Connections could have opted for a debut there versus much easier but opt for this. ELVIS TONY broke 8th of 9 in his debut while getting little tote play. Class drop makes perfect sense. Lone sibling is 2-0-1-0 and earned $18,400. MAYWEATHER missed a Beyer top by a single point in lone local start (2nd at 3-1). Form cycle hints at better as he puts three races tougher. Tactical speed comes in handy as there isn’t much zip in here.

Daily Racing Form is the most trusted source for horse racing news and information. Get an edge when you play the races with DRF.com.

Get more Daily Racing Form horse racing picks on a daily basis on our VSiN Horse Racing page.

Get DRF’s Complete Breeders’ Cup Betting Package with Past Performances, Expert Picks, Clocker Reports and more.

NEW ADDITION OPENS TO THE PUBLIC ON NOVEMBER 13, 2026

New Images and Additional Materials are Here

LOS ANGELES, Oct. 28, 2026 /PRNewswire/ -- The California Science Center's highly anticipated Samuel Oschin Air and Space Center, the permanent home of Space Shuttle Endeavour, will open to the public on November 13, 2026. The Samuel Oschin Air and Space Center is the only place in the world to see a complete, authentic space shuttle system, with a flown orbiter, solid rocket boosters, and external tank, displayed in a 20-story-tall launch configuration. This transformative 200,000-square-foot expansion of the California Science Center nearly doubles its existing exhibit space, showcasing a diverse collection of 100 artifacts, including rare and historic aerospace objects, as well as 100 new hands-on exhibits, featuring interactive and immersive experiences focused on science and engineering.

Guests of all ages will investigate the scientific and engineering principles of atmospheric flight and the exploration of the universe in the Air and Space Center's three multi-level galleries â the Samuel Oschin Shuttle Gallery, the Korean Air Aviation Gallery, and the Kent Kresa Space Gallery. The Samuel Oschin Air and Space Center is the third and final major phase of the California Science Center's three-phase, three-decade master plan to develop one of the world's leading science learning centers.

The Samuel Oschin Shuttle Gallery serves as the star attraction of the Samuel Oschin Air and Space Center. Housing Space Shuttle Endeavour in awe-inspiring launch position, the gallery towers nearly 200 feet high and its exhibits detail how the world's first reusable spacecraft advanced our ability to live and work in low Earth orbit, while laying the groundwork for increasingly ambitious missions into deep space. In addition to preserving a critical chapter in space exploration, the gallery also offers an unparalleled educational experience, allowing guests to view this national treasure and engineering marvel from multiple perspectives and elevations. Additional exhibits in the gallery highlight the shuttle's thermal protection system; its airlock; all 135 space shuttle missions; and tributes to the crews who lost their lives during the Space Shuttle Program.

"The opening of the Samuel Oschin Air and Space Center is the fulfillment of a decades-long dream to create one of the world's leading science centers," said Jeffrey Rudolph, President and CEO of the California Science Center. "With its display of Endeavour in launch position, the Samuel Oschin Air and Space Center will give us a greater platform than ever before to accomplish our mission, to stimulate curiosity and inspire science learning in everyone. This unparalleled educational experience will stand as an enduring source of inspiration for generations of scientists, engineers and explorers."

Lynda Oschin, Chairperson of the Mr. and Mrs. Samuel Oschin Family Foundation, said: "The Samuel Oschin Air and Space Center, and Space Shuttle Endeavour's one-of-a-kind vertical display, is even better than I dreamed. Endeavour exemplifies so many of the passions of my husband â especially astronomy, math, science, exploration, and helping children to achieve their dreams. Years ago, I recognized the extraordinary potential of this project to inspire curiosity, encourage lifelong learning, and open new worlds of possibility for young people. It is thrilling to be just weeks away from welcoming millions of young people to the Samuel Oschin Air and Space Center, named to honor the tremendous legacy and the memory of my husband, a gentleman and a gentle man."

Interactive Experiences, Exhibits, and Artifacts on View

The Samuel Oschin Shuttle Gallery invites guests to engage with interactive experiences, including:

- Launch Tower, a 140-foot ascent aboard an elevator up the shuttle stack leading to a dramatic, glass floor observation platform hovering over the nose of Space Shuttle Endeavour, with out-of-this-world views.

- Shuttle Descent Slide, which drops 45 feet in elevation to represent the shuttle's descent from orbit. Guests will see bright orange light representing the plasma that glows as a shuttle enters the atmosphere and hear a double boom that evokes the sound of the nose and tail as each breaks the sound barrier on return to earth.

- The opportunity to sit inside a replica flight deck and interact with joysticks, switches, lights, buttons and pedals like those that the shuttle commander and pilot would operate.

- The Orbiter Landing Simulator, which will test the piloting ability of guests as they try to land Endeavour on a runway.

In the Korean Air Aviation Gallery guests will view more than a dozen authentic aircraft, from gliders to fighter jets, including the Hawker Siddeley Harrier T.4., Grumman F11F Tiger, and a Pitts Special S-1C, among others. Visitors can also access the forward 70 feet of a Korean Airâoperated Boeing 747 commercial airliner and experience a "flight" from LA to Seoul compressed into a five-minute video journey in an onboard theater presentation.

Other hands-on experiences for guests will include:

- A Wing Shape and Distance interactive, where guests will launch aircraft models with different wing shapes to see how far they fly at different speeds.

- The Launch a Drone Mission interactive. Visitors can launch simultaneous drone missions over a Los Angeles cityscape to learn about everyday applications of autonomous flight.

- Wear-a-Wing invites guests to put on a pair of foam wings and viscerally experience lift.

- Air Race flight simulators put guests in the pilot's seat of iconic aircraft from the Science Center's collection. Guests will be able to choose between the Pitts Special, JN-4 Jenny, and Velie Monocoupe and race for a spot on the leaderboard. Each I360 flight simulator seats 2 guests, has intuitive single-joystick controls, and features full 360-degree rotation.

Among the many exhibits in the Kent Kresa Space Gallery are machines built to explore space, from rockets and robots to space capsules and telescopes, including flown spacecraft like the Mercury-Redstone 2 capsule, Gemini 11 capsule, and Apollo-Soyuz Command Module, among others. Guests also have the opportunity to walk through a section of a real solid rocket booster.

Guests can also:

- Program a Rover and test their skills as a Mars rover driver.

- Lay on their stomachs and pull themselves through the International Space Station in the ISS Fly-Through Simulator, an immersive experience using real footage taken by an astronaut.

- Suit up in a digital space suit.

Opening Weekend

The Samuel Oschin Air and Space Center will open to the public at 10:00 a.m. on Friday, November 13, 2026, after a celebratory program and ribbon-cutting featuring approximately 30 astronauts, including all six crew members from Endeavour's final mission, STS-134, commanded by now U.S. Senator, Mark Kelly. The grand opening will celebrate the culmination of a landmark project and welcome the public, led by hundreds of school children as the first to experience Endeavour in its historic launch configuration for the first time.

To continue the celebration, from Friday, November 13, 2026, at 11:00 a.m., through Sunday, November 15, astronaut and space-related talks will be hosted every half hour through 5:00 p.m. With topics ranging from "women in space" to specific mission overviews, astronauts and experts from NASA Jet Propulsion Laboratory (JPL) and NASA Armstrong Flight Research Center will gather to speak to crowds and answer questions, with no timed reservations required.

November 13, 2026, will also see the premiere of "Endeavour's Long Journey," a photo exhibit documenting Space Shuttle Endeavour's final flight over California, 12-mile, 68-hour journey through the streets of Los Angeles and Inglewood to the Science Center, and the complex, six-month, multi-phase process of stacking each of the space shuttle components in vertical configuration.

Accompanying IMAX movies opening November 13, 2026, include The Dream Is Alive, an unprecedented window on board the space shuttle and an inside look on the astronauts rigorous training; Journey to Space 3D, revisiting three decades of shuttle-era achievements, culminating in Endeavour's journey to the California Science Center; Hubble 3D, the story of the Hubble Space Telescope; and A Beautiful Planet 3D, a portrait of the Earth from space.

Timed Reservations

General admission to the California Science Center, including the Samuel Oschin Air and Space Center, is free. Due to anticipated high demand, there will be timed reservations for entry to the Samuel Oschin Air and Space Center, which can be made in advance for a small $4 service fee. For more information and to make reservations, visit CaliforniaScienceCenter.org. Entry may be limited or unavailable without advance reservations.

Project Team

The Samuel Oschin Air and Space Center was designed by ZGF, with engineering by Arup, construction by MATT Construction, and exhibition design by Evidence Design. Additional project partners include Plas-Tal Manufacturing, responsible for structural steel, and BrandSafway, which provided scaffolding and shuttle protection. The project was developed under the leadership of the California Science Center, with Dennis R. Jenkins serving as Project Director.

Donors

This incredible educational and civic accomplishment has been enabled by the tremendous support of lead donors, the Mr. and Mrs. Samuel Oschin Family Foundation and the State of California; principal donors Korean Air and the Kresa Family Foundation; as well as The Ahmanson Foundation, Thomas and Dorothy Leavey Foundation, W. M. Keck Foundation, The Chuck Lorre Family Foundation, Melanie and Richard Lundquist, The Otis Booth Foundation, Weingart Foundation, and Ibrahim El-Hefni Technical Training Foundation.

VeriSilicon Introduces GLTiny⢠3D GPU Programming Model for Ultra-Low-Power, Memory-Efficient Wearable Devices

Optimized GLTiny Model Brings Rich 3D Graphics to Resource-Constrained Wearable Devices Powered by OpenGL ES GPUs

SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- VeriSilicon (688521.SH) announced GLTiny, an innovative 3D Graphics Processing Unit (GPU) programming model designed for wearable devices with stringent power and memory constraints. Featuring a streamlined Application Programming Interface (API) and an ultra-lightweight driver, GLTiny enables developers to leverage the 3D graphics capabilities of VeriSilicon's Nano OpenGL ES GPU IP series for next-generation smartwatches, smart glasses, and other resource-constrained wearable devices.

Based on VeriSilicon's extensive experience in wearable graphics applications, GLTiny incorporates configurable rendering functions that enable developers to easily define their rendering requirements while efficiently utilizing the underlying OpenGL ES GPU capabilities. This streamlined approach dramatically reduces driver memory footprint and CPU overhead, delivering improved power efficiency and optimized performance for resource-constrained wearable devices.

GLTiny provides native rendering support for standard glTF⢠3D models, allowing developers to directly import glTF content and render it through GLTiny APIs. It supports key features such as lighting models, skeletal skinning, and morph targets, as well as full glTF animation support, including flexible playback, switching between animation clips, and playback speed control. GLTiny also supports visual effects such as Gaussian blur and ripple effects, with simplified APIs designed to streamline 3D graphics development. In addition, GLTiny can be combined with VeriSilicon's VGLite vector graphics driver to form an innovative hybrid driver, enabling coordinated rendering of 2.5D vector graphics and 3D models within the same frame.

"Power consumption and memory footprint are two of the most critical considerations in wearable devices, where delivering rich visual experiences within stringent resource constraints is essential," said Weijin Dai, Chief Strategy Officer, Executive Vice President and General Manager of the IP Division at VeriSilicon. "Leveraging our extensive experience in wearable graphics and close collaboration with leading wearable SoC and device manufacturers, we developed GLTiny to address these challenges. Building on the success of VeriSilicon's VGLite 2.5D GPU programming model, which has become a de facto industry standard for lightweight 2.5D graphics, GLTiny represents another important advancement in our graphics technology portfolio. Designed for seamless integration with the established wearable graphics content development ecosystem, GLTiny operates on VeriSilicon's Nano OpenGL ES GPU IP series, enabling device manufacturers to deliver increasingly sophisticated visual experiences while meeting the stringent power and memory requirements of next-generation wearable devices."

About VeriSilicon

VeriSilicon Microelectronics (Shanghai) Co., Ltd. (VeriSilicon, 688521.SH) is a leading publicly listed provider of custom silicon solutions, with a comprehensive and proprietary portfolio of semiconductor IPs, and a long-standing focus on AI ASIC custom silicon. For more information, please visit: www.verisilicon.com

Media Contact: [email protected]

glTF⢠is a trademark of The Khronos Group Inc.

SOURCE VeriSilicon

Share this article

The Inner Circle acknowledges Dr. Michael M. Pennock, MD, MBiot, DABR, as a Pinnacle Lifetime Member

BEAVER, Pa., Oct. 28, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Michael M. Pennock, MD, MBiot, DABR is recognized as a Pinnacle Lifetime Member for his contributions to Radiation Oncology.

Dr. Michael M. Pennock, a board-certified, dedicated radiation oncologist with the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center, is making a meaningful difference in the lives of cancer patients through his precision, compassion, and commitment to care. Treating adult patients facing a wide range of cancers including lung, breast, head and neck, gastrointestinal, prostate, brain, and spine, Dr. Pennock is known for his meticulous attention to detail and his ability to provide both clinical expertise and emotional reassurance during treatment.

Dr. Pennock's academic foundation began with a Bachelor of Science in psychology, with a concentration in neuroscience, from Davidson College in North Carolina. He went on to earn his Master of Biotechnology from Penn State University, and his Doctor of Medicine from Penn State College of Medicine. He completed his residency in radiation oncology, serving as chief resident in his last year, at Montefiore Medical Center, affiliated with the Albert Einstein College of Medicine in New York City. Dr. Pennock received board certification in radiation oncology from the American Board of Radiology (ABR).

Actively involved in his field, Dr. Pennock is affiliated with the American Society of Radiation Oncology and the American College of Radiation Oncology. His commitment to giving back is reflected in his volunteer efforts with the Leukemia and Lymphoma Society's annual Light the Night event and his involvement with Connecting Champions, where he works with children recovering from cancer.

Throughout his career, Dr. Pennock has been influenced by mentors including Dr. Shalom Kalnicki and Dr. Keyur Mehta. He expresses heartfelt gratitude to his parents, John and Nina Pennock, for their unwavering support throughout his medical journey.

With each patient he treats, Dr. Pennock continues to advance the standards of compassionate care in oncology, guided by a deep sense of purpose and service.

Contact: Katherine Green, 516-825-5634, [email protected]

SOURCE The Inner Circle

Share this article

- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint.

- ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and no plateau was observed, at 13 weeks, a secondary endpoint.

- ASC30 titrated weekly to maintenance doses (40 mg, 60 mg and 80 mg) demonstrated favorable safety and tolerability, with zero study discontinuations due to gastrointestinal adverse events.

- No hepatic safety signal was observed.

HONG KONG, Oct. 28, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today positive topline results from its U.S. Phase II study (NCT07321678) evaluating ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of type 2 diabetes mellitus (T2D). This Phase II study is a 13-week U.S. study evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in 100 participants with diabetes. The primary endpoint is HbA1c reduction from baseline at 12 weeks; one of the secondary endpoints are body weight loss from baseline at 13 weeks. ASC30 (40 mg, 60 mg, 80 mg) met the primary and all secondary endpoints, delivering significant HbA1C reduction and weight loss as well as improvements in multiple cardiovascular risk factors. T2D is the second indication in development for ASC30, in addition to obesity.

For the primary endpoint, ASC30 demonstrated statistically significant and clinically meaningful HbA1c reduction in participants with diabetes compared to placebo (p 0.0001). Placebo-adjusted HbA1c reductions from baseline were 1.7%, 1.6% and 1.7% (least squares mean) for 40 mg (n=20), 60 mg (n=29) and 80 mg (n=28), respectively, at 12 weeks, using the efficacy estimand[1]. Participants had an average HbA1c of 8.3% at baseline.

For the secondary endpoint of body weight reduction, ASC30 demonstrated statistically significant and clinically meaningful body weight reduction compared to placebo (p = 0.001 to 0.003). Placebo-adjusted body weight reduction from baseline was 4.4%, 3.8% and 4.0% (least squares mean) for 40 mg (n=20), 60 mg (n=29) and 80 mg (n=28), respectively and no plateau was observed, at 13 weeks, using the efficacy estimand. Participants had an average body weight of 93.7 kg at baseline.

Although titration (once weekly) was fast in the study, ASC30 continued to demonstrate favorable gastrointestinal (GI) tolerability. ASC30 titrated weekly to maintenance doses (40 mg, 60 mg and 80 mg) demonstrated favorable safety and GI tolerability, with zero study discontinuations due to GI adverse events (AEs). The favorable GI tolerability in diabetic participants was consistent with the finding from studies in obese or overweight participants. It is anticipated that GI tolerability will significantly improve in the Phase III diabetic program when titration is slowed down to once every four weeks. There was only one study discontinuation (1/80, 1.3%, hiccup) due to any AEs. The placebo group had zero study discontinuation due to any AEs.

In this ASC30 U.S. Phase II diabetic study, all drug-related AEs were only grade 1 (mild) and grade 2 (moderate) in severity. There were no drug-related serious AEs (SAEs).

The overall safety profile of ASC30 in diabetic participants was consistent with that observed in another Phase II study (NCT07002905) in participants with obesity or overweight. No hepatic safety signal was observed. There were no elevations of alanine transaminase (ALT), aspartate aminotransferase (AST), or total bilirubin (TBL) during the treatment period. For all other safety signals, ASC30 demonstrated a favorable safety profile in diabetic participants.

"These data demonstrate that ASC30 has the potential to be a best-in-class oral small molecule GLP-1 for diabetes, in addition to a best-in-class oral small molecule GLP-1 for obesity as demonstrated by the efficacy and tolerability from our U.S. Phase II study in participants with obesity or overweight," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, "The combination of significant HbA1c reductions, weight loss and favorable tolerability reinforces our confidence in advancing ASC30 as a once-daily oral treatment option for patients with type 2 diabetes."

ASC30 was discovered and developed in-house at Ascletis as an investigational small molecule GLP-1R fully biased agonist. The ASC30 global Phase III program for obesity has two pivotal trials (AURORA-1 NCT07743463 and AURORA-2 NCT07743450) in the U.S., Europe, and Canada and is currently enrolling approximately 4,600 participants with obesity or overweight. Topline data from the ASC30 global Phase III clinical program for obesity are expected in the third quarter of 2028, with a U.S. Food and Drug Administration (FDA) New Drug Application (NDA) submission for obesity expected by the end of 2028 and a European Medicines Agency (EMA) Marketing Authorisation Application (MAA) submission for obesity expected in early 2029. ASC30 has the potential to become the second oral small molecule GLP-1 receptor agonist available in the U.S. and Europe, if approved.

[1] The efficacy estimand is the primary estimand which evaluates the treatment effect of all randomized eligible participants while adhering to treatment.

About the U.S. Phase II Study with ASC30 for the Treatment of Diabetes

The Phase II study is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 tablets in participants with type 2 diabetes mellitus (7.0% ⤠HbA1c ⤠10.5% at baseline). The primary endpoint of the Phase II study is the change from baseline in HbA1c at 12 weeks in the treatment group compared with the placebo group. Secondary endpoints include the change from baseline in body weight at 13 weeks in the treatment group compared with placebo group. The Phase II study enrolled 100 participants with type 2 diabetes mellitus at multiple sites across the U.S. The participants were randomly assigned in a ratio of approximately 2:3:3:2 to 40 mg, 60 mg and 80 mg ASC30 tablets and matching placebo tablets, respectively. ASC30 was titrated weekly from 1 mg to maintenance doses of 40 mg, 60 mg and 80 mg.

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose combination (FDC) of ASC30 and ASC39, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo

ICR Healthcare

443-231-0505 (U.S.)

[email protected] 

Ascletis Pharma Inc. PR and IR Teams

+86-181-0650-9129 (China)

[email protected]

[email protected] 

SOURCE Ascletis Pharma Inc.

Share this article

Winners applied AI across product development, claims, and software delivery, reducing manual work and speeding results

LAS VEGAS, Oct. 28, 2026 /PRNewswire/ -- CONNECTIONS CONFERENCE -- Guidewire (NYSE: GWRE) congratulates the winners of its 2026 Innovation Awards: Beazley, Definity, and RCIS. The annual awards honor Guidewire customers for their innovation in addressing evolving business needs, driving better experiences for their customers and agents, and delivering better results across the insurance lifecycle. Winners were announced during Guidewire Connections, the company's annual customer conference.

The three 2026 Innovation Award winners are:

1. Beazley

Modernization across product development, broker submissions, and billing is helping Beazley improve speed and efficiency while creating a foundation for growth.

Beazley, a leading Lloyd's syndicate and global specialty insurer, is transforming its policy administration and billing capabilities through a modern, connected Guidewire Cloud platform, creating a consistent global foundation while retaining the flexibility required for local market variations. Working with Capgemini, a Guidewire Consulting Global Strategic partner, Beazley implemented Guidewire PolicyCenter and BillingCenter, with the European solution delivered in approximately eight months.

The program addresses significant complexity across Beazley's global specialty business, including rationalizing more than 200 marketable products into a condensed, streamlined set of products which reduced complexity and improved speed to market. Capgemini's AI-enabled delivery model, combined with Guidewire's Advanced Product Designer (APD), established a repeatable Product Factory approach enabling rapid development.

The transformation also connects Beazley's digital and broker platforms with its core underwriting operations through Guidewire Integration Gateway, using API and event-driven integration to support broker submissions, customer and account data and policy servicing. Combined with a modernized billing capability, this creates a more connected digital insurance lifecycle and supports Beazley's evolution towards increasingly AI-enabled underwriting.

These capabilities provide Beazley with a scalable modern core that simplifies the underlying technology landscape while supporting greater automation, product agility and continued growth across global specialty markets.

For additional information, visit the Beazley website.

2. Definity

Definity launched its first production agentic AI solution to manage and triage broker First Notice of Loss (FNOL) intake, replacing manual data re-keying with structured draft claims generated directly in Guidewire for a claims adjuster to review.

Developed in collaboration with Deloitte, a Guidewire Consulting Global Premier partner, the solution leverages a network of AI agents to classify submissions, extract and reason over information, and execute workflows to generate structured draft claims directly in ClaimCenter. It provides a governed, traceable path from AI processing to claims operations, keeping adjusters firmly in the loop while reducing manual effort and improving speed and consistency.

Beyond modernizing FNOL intake, the initiative establishes a scalable foundation for deploying reusable, governed agentic AI capabilities across Definity's claims lifecycle, accelerating future innovation.

For additional information, visit the Definity website.

3. RCIS

RCIS Tech Transformation in Crop Insurance, one of the insurance industry's most complex and highly regulated lines of business, is modernizing operations with Guidewire InsuranceSuite, Jutro Digital Platform, data, and AI-first innovation

As part of its Passion for the Possible⢠initiative, RCIS enlisted PwC, a Guidewire Consulting Global Strategic partner, to transform its legacy environment into a modern, unified platform powered by Guidewire Cloud Platform, delivering enhanced digital experiences for agents, underwriters, adjusters and customers.

Led by its vision to evolve in technology, ease and modern customer experience, RCIS and PwC leveraged Guidewire Advanced Product Designer (APD), Digital and AI-first engineering to accelerate delivery of a highly customized crop insurance solution. The transformation includes complex legacy data migration, integrated geospatial Farm Maps, automated Risk Management Agency (RMA) regulatory reporting, and streamlined core insurance operations all while maintaining business continuity through critical seasonal agricultural cycles. RCIS is among the top providers of crop insurance in the U.S. and one of only 12 Approved Insurance Providers (AIPs) of the Federal Crop Insurance Program. It is the only AIP to offer coverage in all 50 U.S. states through a national network of more than 3,700 agents.

It is anticipated the RCIS Guidewire transformation will set a new benchmark â in the agriculture industry and across the insurance industry as a whole - for modernizing complex insurance platforms, combining Guidewire Cloud innovation, deep industry expertise, and AI-first engineering to accelerate transformation and deliver measurable business value.

For additional information, visit the RCIS website.

"We congratulate this year's Innovation Award winners and thank all participants and our consulting partners for their contributions," said Brian Desmond, CMO, Guidewire. "These insurers applied AI to the work that runs their business and have measurable results to show for it. Agentic insurance is where the industry is heading: AI agents that execute work within the controls the insurer sets. These winners are showing how to get there, on Guidewire."

About Guidewire

Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. More than 570 insurers in 44 countries, from new ventures to the largest and most complex in the world, rely on Guidewire products. With core systems leveraging data and analytics, digital, and artificial intelligence, Guidewire defines cloud platform excellence for P&C insurers.

We are proud of our unparalleled implementation record, with 1,700+ successful projects supported by the industry's largest R&D team and consulting partner ecosystem. Our marketplace represents the largest partner community in P&C, where customers can access hundreds of applications to accelerate integration, localization, and innovation.

For more information, please visit www.guidewire.com and follow us on X and LinkedIn.

Contact:

Melissa Cobb

Director, Public Relations

Guidewire Software, Inc.

+1.650.464.1177

[email protected]

NOTE: For information about Guidewire's trademarks, visit https://www.guidewire.com/legal-notices.

SOURCE Guidewire Software

Share this article

The Inner Circle acknowledges David R. Neff, DO as a Pinnacle Lifetime Member

EAST LANSING, Mich., Oct. 28, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, David R. Neff, DO is acknowledged as a Pinnacle Lifetime Member for his contributions in Medicine, Education, and Research.

David R. Neff, DO, has built a distinguished career spanning more than 45 years in medicine, healthcare leadership, medical education, and pharmaceutical research. Throughout his career, he has remained committed to advancing patient care, promoting medical innovation, and mentoring future generations of healthcare professionals.

As Principal and Chief Executive Officer of David Neff DO PLLC, Dr. Neff provides comprehensive medical care focused on infectious diseases, cancer, diabetes, cardiometabolic disorders, pain management, hospice and palliative care, and family medicine. His practice emphasizes patient-centered care, shared decision-making, and improving quality of life through personalized treatment strategies.

Dr. Neff earned a Bachelor of Science degree in Physiology and Biochemistry from Michigan State University before receiving his Doctor of Osteopathic Medicine degree from Michigan State University College of Osteopathic Medicine in 1980. He completed a rotating internship and family medicine residency at Lansing General Hospital and later pursued a fellowship in clinical biomechanics at Michigan State University. He is board certified in family medicine.

Widely respected for his expertise in family and community medicine, genomics, pain management, infectious disease diagnostics, diabetes care, and pharmaceutical development, Dr. Neff has dedicated his career to integrating scientific innovation with compassionate patient care. His work also includes consulting on cardiometabolic, renal, and hepatic syndromes, muscular dystrophy, and long-acting injectable antipsychotic therapies.

Over the course of his career, Dr. Neff spent approximately 20 years in direct clinical practice before transitioning into the pharmaceutical industry, where he served for 15 years in leadership roles. His positions included Medical Science Liaison at Merck and Senior Chief Medical Director for Medicaid Medical Affairs. During this time, he played an important role in advancing pharmaceutical research, physician education, and healthcare policy initiatives.

When the COVID-19 pandemic emerged, Dr. Neff returned to direct patient care, serving patients in urgent care and family medicine settings. His decision reflected a lifelong commitment to serving communities and addressing healthcare needs during times of crisis.

In addition to his clinical and industry accomplishments, Dr. Neff has made significant contributions to medical research and education. His research has been published in the prestigious New England Journal of Medicine, including work involving genomics and advanced diagnostic methodologies. He has also co-authored multiple publications with members of the American College of Cardiology and has been a frequent regional and national speaker on pain management and pharmaceutical drug discovery.

Today, Dr. Neff serves as a Clinical Professor at Michigan State University College of Osteopathic Medicine, where he helps educate and mentor future physicians. He is actively involved in numerous professional organizations, including the American Osteopathic Association, Michigan Osteopathic Association, Michigan Health and Hospital Association, National Lipid Association, American Diabetes Association, American Heart Association, and American College of Cardiology.

Beyond his professional responsibilities, Dr. Neff volunteers with the U.S. Pain Foundation and serves on the board of the Care Free Clinic in Lansing, Michigan, helping expand access to healthcare services for underserved populations.

Outside of medicine, he enjoys golfing and downhill skiing. He credits much of his success to the guidance of early mentors, including a high school guidance counselor who encouraged him to pursue his goals and professional aspirations.

Dr. Neff is grateful for the support of his wife, Elizabeth, and their three children, whose encouragement has been an important part of his personal and professional journey.

Looking ahead, Dr. Neff plans to devote more time to teaching and mentoring medical students, residents, and fellows while continuing to advance healthcare through education, research, and clinical excellence. Guided by a philosophy rooted in compassion, partnership, and informed medical decision-making, he remains committed to helping patients achieve the highest possible quality of life while inspiring the next generation of healthcare leaders.

Contact: Katherine Green, 516-825-5634, [email protected]

SOURCE The Inner Circle

Share this article

Breeders’ Cup Juvenile 2026

Will we be looking at the stars of tomorrow or just this year’s most promising prospects? The Breeders’ Cup Juvenile is the headline race of Friday’s Keeneland Race Course card, as seven of the nation’s top 2-year-olds run for the biggest wins of their careers. This 1 1/16-mile race over the Lexington, KY dirt is worth a lot of points on the 2027 Road to the Kentucky Derby and also worth a lot of money, with a prize purse of $2 million up for grabs. Post time for Race 9 is set for 4:55 p.m. ET on Friday, October 30.

We’ve got all kinds of horse racing coverage this week from myself, Ed Sehon, and Dave Tuley, plus more handicaps from our friends at Daily Racing Form. See it all here.

Here are the Breeders’ Cup Juvenile post positions, horses, jockeys, trainers, and odds.

Hughes was installed as the even-money morning line favorite for Bob Baffert, who has two horses in this race as he looks for his seventh career win in the BC Juvenile. Todd Pletcher has two entries as well, including American History, who many believe will wind up going off as the second favorite. Pletcher has won this race five times himself. Gaudreau was scratched early in the week, so his absence isn’t a surprise and the horses just slide over one spot in the starting gate.

Here are some thoughts on the horses in the BC Juvenile field:

1. Damavand (20-1; Saez/Pletcher): Amo Racing is hoping that their $1 million investment pays off quickly, as the son of Not This Time and Tempers Rising heads out for his third career start. He’s won on this dirt and at this distance, breaking his maiden back on Oct. 4 after a rough first race, finishing fourth over just six furlongs. Luis Saez gets the ride here after John Velazquez had that win earlier this month. Damavand started really slow in that 13-horse field, but was the best closer. With Gaudreau scratched, maybe Damavand won’t get as far behind here.

2. Gaudreau (SCR; Franco/Brown): Gaudreau, who was 8-1 on the morning line, was scratched on Wednesday with a fever.

3. Salahudin (6-1; Gaffalione/Baffert): Salahudin runs at Keeneland for the first time after winning the Iroquois Stakes at Churchill Downs on Sept. 12. He’s 3-for-3 under two different riders and now Tyler Gaffalione gets the mount with Jose Ortiz on Coach Pope and Florent Geroux recovering from broken ribs. The son of Uncle Mo and Smart Strike has gotten better in each race and has gone a longer distance in each one. He won the Iroquois by a half-length of He Is No Lie, who is a much longer shot at 15-1. Take that for what it’s worth.

4. Earth Song (20-1; Alvarado/Delgado): The son of Justify broke his maiden in his debut on Sept. 7 and then really leveled up in class, finishing fourth at Belmont in the G1 Champagne over one mile. Nobody had a chance against U. S. S. Valor, who won running away, with Gaudreau second. Ricardo Santana Jr. had that ride and seemed to pull him back on the straightaway after he made contact with the eventual winner. Recent works, and that data point, suggest that maybe he’s not quite ready for this caliber of field. But, it will be interesting to see if it was the rider or the horse who peeled back in the Champagne.

5. Hughes (1-1; Prat/Baffert): There is a lot of money behind this Into Mischief colt, as numerous ownership groups are included among the connections. So far, so good, as Hughes has entered four races and won them all, including two G1 wins – the American Pharaoh last time out at Santa Anita on Oct. 3 and the Del Mar Futurity on Sept. 6. Obviously there are some questions with the Baffert barn shipping him about 80% of the way across the country to Lexington. It will also not be Juan Hernandez, Baffert’s big-money rider in California, in the mount. It will be Flavien Prat. He’s a deserving favorite, but there may not be a ton of interested parties at that price.

6. American History (9/2; Velazquez/Pletcher): This is an apropos name for a horse with such a rich bloodline, as sire Constitution and dam Bloody Point made a lot of history themselves and there are siblings and cousins of those two all over the place that have racked up earnings as well. Johnny Velazquez has a closer here with a win on this track and at this distance, a win that came over Coach Pope, whose price is similar in this event. American History was the third favorite in the Claiborne Breeders’ Futurity, so was he underestimated going into that race or could that last effort have been something of a fluke?

7. Coach Pope (4-1; J. Ortiz/McPeek): Jose Ortiz gets a shot at revenge on the Keeneland dirt here, as he had the favorite in that Claiborne Breeders’ Futurity, but couldn’t hold off American History. The son of Tapit and Gamble’s Ghost by way of Ghostzapper has only won once in three tries. His other second-place finish came against Gaudreau, but he did beat U. S. S. Valor for second. Ortiz may have learned some valuable information last time out that could be used to his advantage here and the morning line with slight priority towards him over American History could be an intriguing context clue.

8. He Is No Lie (15-1; Rosario/O’Neill): The outside post belongs to He Is No Lie, whose best outcome was second in the Iroquois Stakes to Salahudin. The son of Early Voting and Truth In The Lies, two pretty ideal names with Election Day coming up on Nov. 3, won his maiden back in May at Santa Anita and is 0-for-3 since, bouncing back-and-forth between California and Kentucky.

Breeders’ Cup Juvenile Picks

Gaudreau’s absence is fascinating here. He probably wouldn’t have won the race, but he probably would have set the early pace. There are always questions with two turns for 2-year-olds, and some have already answered those questions, but now the ride philosophy may shift for some of the jocks with what should be a slower pace at the outset. Closers may be able to conserve energy, but so will pressers that would have wanted to stay within a couple lengths.

I’ll go with 6 American History over 5 Hughes, 1 Damavand, and 3 Salahudin. Kenny McPeek only has two graded stakes winners this year and those have come in G2 and G3 races. Maybe Coach Pope has it in him here, but I like others more. Damavand has the chance to be a really deep closer with the distance here, and I think he will pass tiring rivals. But, it’ll be American History and Hughes head-for-head and I’ll take the horse tested outside of California, with a win at Keeneland.

6 American History

5 Hughes

1 Damavand

3 Salahudin

For more coverage, check out our horse racing page.

Luxury Oceanfront Villa Alegria Anguilla Announces Complimentary 7th Night for Christmas 2026 Caribbean Holiday Vacations

ANGUILLA, British West Indies, Oct. 28, 2026 /PRNewswire/ -- Travelers looking to relax in the Caribbean this festive season have a compelling new reason to book Anguilla. Villa Alegria, a standout luxury villa on the island's desirable West End, is offering a complimentary seventh night for stays from November 28 through Christmas week 2026. This limited-time offer applies to new reservations booked directly by guests or their preferred travel advisor. Visit www.AlegriaAnguilla.com to check availability and request to book.

Located oceanfront in upscale Cul de Sac with a path to Sandy Point Beach, Villa Alegria provides families and private groups with resort-style amenities, expansive living spaces, and sweeping views of the Caribbean Sea and the mountains of St. Martin.

Anguilla Holiday Villa Rental Specials Details

Guests enjoy a complimentary seventh night when they book a 7 or more-night stay over these eligible dates:

- Pre-Holiday Stay Dates: November 28 â December 16, 2026, at $2,900 USD per night

- Christmas & Festive Stay Dates: December 17 â December 27, 2026, at $6,500 USD per night

- Terms: Minimum 7 consecutive nights stay. Additional 13% GST and a 10% service charge. Offer is subject to villa availability and change.

World-Class Luxury Destination

Anguilla continues to rank among the Caribbean's top vacation destinations, recently recognized as the region's safest island for the past two years, and named the Caribbean's Leading Luxury Island Destination and Leading Culinary Destination at the 2026 World Travel Awards. Global luxury travel network Virtuoso also listed Anguilla as the #1 Caribbean destination for this festive holiday season.

Oceanfront Privacy with Full-Service Villa Amenities

Designed by owners Neil and Wendy Freeman with interiors by award-winning designer Susan Butcher, Villa Alegria combines private vacation home independence with full-service hospitality. Guests enjoy oceanfront views with a paved walkway leading to Sandy Point Beach for swimming and snorkeling, and are within minutes from Anguilla's premier attractions: Meads Bay, Rendezvous Bay, Greg Norman-designed championship golf, tennis, and fine-dining restaurants.

- Accommodations: 4 spacious king-bedroom suites with private en-suite bathrooms and ocean-facing terraces, plus a dedicated media room with a queen sofa bed serving as a 5th bedroom. Ground-floor primary suites provide step-free accessibility.

- Beach Access: Paved path to Sandy Point Beach. Beach chairs and optional beach butler/drink service can be arranged.

- Outdoor Living: One of Anguilla's largest private infinity pools, a heated hot tub, covered dining porticos, and an outdoor gas grill.

- Wellness & Recreation: Private indoor gym with Peloton bike, snorkeling equipment and beach games.

- Comfort & Convenience: Chef's kitchen, individually zoned air conditioning in bedrooms, bathrooms, media room and gym, plus high-speed Wi-Fi suited for remote work and streaming.

- Dedicated Staff: Daily housekeeping (MondayâSaturday) and full concierge service to arrange optional services (additional charges may apply) including private chef dining, villa or beach butlers, air/sea boat transfers, rental cars, grocery provisioning, in-villa spa treatments, island excursions, and childcare.

"Demand for luxury hotels, resorts and villas is high during the winter holidays in Anguilla. Villa Alegria gives families and groups the best of all worlds: space, privacy, rich amenities and professional concierge support, without the crowds." said Owner Neil Freeman.

How to Book Villa Alegria Anguilla:

To request to book Villa Alegria Anguilla, visit the villa's website at www.AlegriaAnguilla.com or contact owner Neil Freeman directly at +1 (312) 907-8486 or [email protected]. Professional travel agent referrals are welcome. Follow Alegria on Facebook @villaalegriaanguilla or Instagram @villaalegriaanguillabwi. Offers are subject to availability and change at any time. Optional services are at additional charge.

About Villa Alegria Anguilla: Villa Alegria Anguilla is a luxury, 4/5-bedroom private oceanfront vacation home on Anguilla's West End combining incredible views of the Caribbean Sea and St. Martin's mountains, effortless beach access down a paved path, stunning architecture, exceptional amenities and personalized concierge service. Guests enjoy a private, luxury vacation experience with all the comforts of home.

SOURCE Villa Alegria Anguilla

Share this article

/C O R R E C T I O N - Honeywell Aerospace Inc./

In the news release, Honeywell Aerospace reports third quarter results; updates 2026 outlook, issued 28-Oct-2026 by Honeywell Aerospace Inc. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:

Honeywell Aerospace reports third quarter results; updates 2026 outlook

- Sales of $4.6 billion, reported and organic1 sales up 2% year over year

- Net income of $0.7 billion; adjusted EBIT1 of $1.2 billion, up 1% despite incremental standalone costs

- Raises full-year pro forma standalone adjusted earnings per share1 and second half free cash flow1 guidance

- Board declares inaugural quarterly dividend payment of $0.40 per share on the company's common stock

PHOENIX, Oct. 28, 2026 /PRNewswire/ -- Honeywell Aerospace (Nasdaq: HONA) today announced results for the third quarter and declared its first quarterly dividend. The company also raised its full-year 2026 pro forma standalone adjusted earnings per share1 and second half 2026 free cash flow1 guidance ranges, maintained its full-year organic1 sales outlook, and narrowed its full-year pro forma standalone adjusted EBIT1 guidance range.

"Honeywell Aerospace delivered results above our expectations in its first quarter as a standalone company, increasing sales and adjusted EBIT sequentially and year over year as we accelerate investments to drive greater output and better serve our customers. Demand for our solutions remains robust with 9% orders growth over the last 12 months," said Jim Currier, Chief Executive Officer of Honeywell Aerospace. "We are seeing encouraging signs from pacing suppliers as we deepen our commitment to enduring partnerships. This progress, combined with ongoing qualification of additional material sources, positions us for higher sales and output growth in 2027 and beyond."

Initial dividend declaration

Honeywell Aerospace's Board of Directors has approved a quarterly cash dividend of $0.40 per share of its common stock. The dividend is payable on December 4, 2026, to shareholders of record as of the close of business on November 13, 2026.

Currier added, "The Board's decision to declare a regular dividend underscores the visibility into our durable free cash flow growth in the years ahead. Paying a competitive, growing dividend is a key component of our capital allocation strategy designed to deliver substantial shareholder value while maintaining financial flexibility and a strong investment-grade credit rating."

Recent Honeywell Aerospace highlights

- Year to date, the company has secured more than $20 billion in new wins (estimated lifetime value) supported by the following announcements:

- The U.S. Air Force advanced Honeywell Aerospace's SkyShot 1600 engine, which is designed to meet all mission-critical performance parameters for collaborative combat aircraft and unmanned aircraft systems, into Preliminary Design Review as part of its Autonomous Collaborative Platform program.

- Honeywell Aerospace secured over $2 billion in new awards to provide its advanced navigation and RF systems for several missiles and munitions programs, including some initial contracts on platforms prioritized by the Munitions Acceleration Council.

- The City of Phoenix Aviation Department signed an agreement with Honeywell Aerospace to study how to translate the company's Surface Alert (SURF-A) technology to ground vehicle operators on tarmacs, taxiways, and runways at three local airports, including Phoenix Sky Harbor International.

- The company announced a 300,000 square foot expansion of its Tempe, Arizona manufacturing facility, expected to open in late 2028. The new facility adds capacity, lean manufacturing, automation, and supply-chain resilience to support current Control Systems production, recent wins, and next generation platforms.

- Honeywell Aerospace presented an update on its supply chain transformation at a September investor conference. Key messages from the presentation included root causes and actions underway for the constraints from a small number of mechanical suppliers currently limiting output growth.

Summary financial results

Honeywell Aerospace sales for the third quarter increased 2% on a reported and organic¹ basis year over year. Backlog grew to $19.3 billion at quarter end, up 12% from the prior year, and trailing twelve-months orders were up 9%, led by Defense and Space. Adjusted EBIT1 was up 1%, including both an approximately $50 million net benefit from International Emergency Economic Powers Act (IEEPA) tariff refunds and new costs necessary as an independent public company.

End market sales

Commercial Original Equipment sales were up 7% on a reported basis and 8% organically1 to $0.7 billion as commercial air transport build rates and selectable equipment volumes increased. Commercial Aftermarket sales of $2.1 billion grew 2% year over year, driven by healthy underlying demand limited by mechanical component availability. Defense and Space sales of $1.8 billion expanded 1%, as strong growth led by the CAES and Civitanavi acquisitions was partially offset by lower international volumes due to supply constraints and the wind-down of a non-aerospace restricted government program.

2026 outlook

Based on third quarter results and current outlook, Honeywell Aerospace updated its prior full-year and second half guidance ranges.

Segment results

Electronic Solutions sales grew 4% year over year on a reported basis and 5% organically¹, led by strength in Commercial Original Equipment and Defense and Space. Segment adjusted EBIT¹ increased by 11% year over year as tariff refunds and pricing more than offset unfavorable mix and higher costs.

Engines and Power Systems sales increased 3% year over year on a reported basis and 2% organically¹, led by higher Commercial Aftermarket volumes. Segment adjusted EBIT¹ decreased 16% year over year as unfavorable mix and higher costs more than offset price and the impact of tariff refunds.

Control Systems sales were flat year over year on a reported and organic¹ basis as Defense and Space growth was offset by a decline in Commercial Aftermarket. Segment adjusted EBIT¹ increased 2% year over year as price more than offset higher costs and unfavorable mix.

Conference call details

Honeywell Aerospace will discuss its third quarter results and full-year 2026 guidance during an investor conference call starting at 5:00 pm EDT today. A live webcast of the investor call as well as related presentation materials will be available through the Investor Relations section of the company's website (investor.honeywellaerospace.com). A replay of the webcast will be available for 30 days following the presentation.

About Honeywell Aerospace

Honeywell Aerospace (Nasdaq: HONA) is an independent global aerospace and defense company whose critical technologies are broadly deployed on the world's leading commercial air transport, business aviation, defense and space platforms. These integrated solutions enable safer, more efficient, and more reliable missions. Headquartered in Phoenix, Arizona, the company employs more than 36,000 people globally and supports more than 10,000 customers. With a broad portfolio spanning avionics and navigation systems, engines and power systems, and control systems for aircraft, Honeywell Aerospace combines commitment and deep engineering expertise to drive innovation and long-term value for the aerospace industry. For more information, visit www.honeywellaerospace.com or follow Honeywell Aerospace on LinkedIn. 

Additional information 

Honeywell Aerospace uses our Investor Relations website, investor.honeywellaerospace.com, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD.  Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, public conference calls, and webcasts.

Forward-looking statements

We describe many of the trends and other factors that drive our business and future results in this release. These discussions contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are those that address activities, events, or developments that management intends, expects, projects, believes, estimates, forecasts, or anticipates will or may occur in the future. They are based on management's assumptions and assessments in light of past experience and trends, current economic and industry conditions, expected future developments, and other relevant factors, many of which are difficult to predict and outside of our control.

Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those reflected in such statements. Important factors that could cause Honeywell Aerospace's actual results to differ materially from those projected in any forward-looking statements include, but are not limited to: (i) risks relating to Honeywell Aerospace's spin-off from Honeywell International Inc.